盐酸可乐定(Clonidine Hydrochloride) - 药物靶点：ADRA2_在研适应症：注意缺陷障碍伴多动，偏头痛，血管性头痛_专利_临床

概要

基本信息

简介可乐定通过刺激大脑中的 α2 受体来降低血压，这会导致许多动脉松弛。可乐定于 1961 年获得专利，并于 1966 年投入医疗用途。可乐定以 Catapres 等品牌销售，是一种 α2-肾上腺素能激动剂药物，用于治疗高血压、多动症、戒毒（酒精、阿片类药物或尼古丁）、更年期潮红、腹泻、痉挛和某些疼痛状况。它可通过口服、注射或作为皮肤贴剂使用。起效通常在一小时内，对血压的影响可持续长达八小时。常见的副作用包括口干、头晕、头痛、低血压和嗜睡。严重的副作用可能包括幻觉、心律失常和意识模糊。如果迅速停止，可能会出现戒断效应。

药物类型

小分子化药

别名

2,6-Dichloro-N-2-imidazolidinylidenebenzenamine、2-((2,6-Dichlorophenyl)imino)imidazolidine、Chlofazoline

+ [35]

靶点

ADRA2

作用方式

激动剂

作用机制

ADRA2激动剂(肾上腺素能受体α-2家族激动剂)

治疗领域

神经系统疾病心血管疾病眼部疾病+ [2]

在研适应症

注意缺陷障碍伴多动偏头痛血管性头痛+ [5]

非在研适应症

化疗性口腔黏膜炎糖尿病性神经病变腰骶神经根病变+ [4]

原研机构

Boehringer Ingelheim GmbH

在研机构

宜昌人福药业有限责任公司

湖北远大天天明制药有限公司Medical Parkland Co., Ltd.

+ [7]

非在研机构

Valerio Therapeutics SA

Boehringer Ingelheim GmbH

Monopar Therapeutics, Inc.

+ [3]

权益机构

Valerio Therapeutics SA

Æterna Zentaris, Inc.Strongbridge Ireland Ltd.

+ [5]

最高研发阶段批准上市

首次获批日期

日本 (1969-05-15),

原发性高血压肾性高血压高血压

最高研发阶段(中国)批准上市

特殊审评孤儿药 (美国)、孤儿药 (欧盟)、优先审评 (中国)

登录后查看时间轴

结构/序列

分子式C9H10Cl3N3

InChIKeyZNIFSRGNXRYGHF-UHFFFAOYSA-N

CAS号4205-91-8

关联

558

项与盐酸可乐定相关的临床试验

IRCT20120527009878N11

/ Suspended临床2期IIT

Role of clonidine in management of pain after lumbar discectomy

开始日期2640-01-26

申办/合作机构

Tabriz University of Medical Sciences

CTRI/2025/04/085425

/ Not yet recruitingN/AIIT

Comparison of Combination of Ketamine and Clonidine With Alkalinised Lignocaine For Cuff Inflation in the Reduction of Postoperative Sore Throat - nil

开始日期2025-05-17

申办/合作机构-

NCT06447194

/ Not yet recruiting临床1/2期IIT

Effect of Local Injectable Ropivacaine, Epinephrine, Clonidine, and Ketorolac (RECK) Anesthetic Cocktail on Postoperative Pain in Posterior Spinal Fusion

"RECK" is a combination of local anesthesia medications, used for the purpose of pain control. RECK is an acronym which stands for Ropivacaine, Epinephrine, Clonidine, and Ketorolac. The purpose of this study is to investigate the effect of RECK local injectable anesthetic in the setting of posterior spinal fusion. Our specific aims are the following.
Primary aim: to investigate the effect of RECK local injectable anesthetic on postoperative VAS pain scores.
Secondary aims: to investigate of effect of RECK injection on postoperative opioid consumption and hospital length of stay.
Hypothesis: RECK injection will significantly decrease postoperative VAS pain score, opioid consumption, and hospital length of stay compared to placebo controls.

开始日期2025-04-01

申办/合作机构

University of Maryland Baltimore

100 项与盐酸可乐定相关的临床结果

登录后查看更多信息

100 项与盐酸可乐定相关的转化医学

登录后查看更多信息

100 项与盐酸可乐定相关的专利（医药）

登录后查看更多信息

20,380

项与盐酸可乐定相关的文献（医药）

2025-07-01·ACTA ANAESTHESIOLOGICA SCANDINAVICA

Intraoperative Clonidine in Spine Surgery: A Randomised Controlled Trial.

Article

作者: Birkebæk, Stine ; Rasmussen, Mikkel Mylius ; Uhrbrand, Peter Gaarsdal ; Nikolajsen, Lone ; Juul, Niels

Patients undergoing spine surgery often experience post-operative pain. In this context, clonidine, an alpha-2 agonist, may be relevant due to its analgesic properties. We conducted a randomised, double-blinded, placebo-controlled trial to evaluate the effect of a single dose of intraoperative intravenous clonidine on post-operative opioid consumption, pain intensity and side effects. Patients undergoing spine surgery at Aarhus University Hospital, Denmark, were randomised to receive intraoperative clonidine (3 μg/kg) or placebo. The primary outcome was opioid consumption within the first 3 h after surgery. Secondary outcomes included opioid consumption within the first 6 h, pain intensity at rest and during coughing, post-operative nausea and vomiting (PONV), and sedation in the post-anaesthesia care unit (PACU). Additional outcomes included time to discharge from the PACU, length of hospital stay and daily opioid consumption after 1 month. Data from 120 patients (49 females, 71 males, mean age 65 ± 14 years) were available for analysis; 61 received clonidine and 59 received placebo. Post-operative intravenous morphine equivalents within 3 h were similar in the clonidine group 5 mg (0-15) and the placebo group 10 mg (0-15) (p = 0.58). Pain intensity at rest was 4 (0-5.5) in the clonidine group and 3 (0-5) in the placebo group upon arrival at the PACU (p = 0.20). No differences were observed between the clonidine and placebo groups regarding any secondary outcomes, except for hypotension, which was more frequent in the clonidine group (24 vs. 13 patients). A single dose of intraoperative clonidine did not reduce post-operative opioid consumption or pain intensity in patients undergoing spine surgery.

2025-06-01·KNEE

Periarticular injection versus placebo in total knee arthroplasty with intrathecal morphine

Article

作者: Lombardo, Daniel J ; Ross, Jeremy A ; Johnson, Aaron J ; Jiranek, William A ; Golladay, Gregory J ; Potter, Teresa ; Tocks, Gregory

INTRODUCTION:

Periarticular injection (PAI) is one part of total knee arthroplasty (TKA) multimodal analgesia protocols. PAI combined with neuraxial anesthesia including intrathecal morphine (ITM) has not been previously investigated. This study prospectively compares PAI to placebo injection in patients undergoing TKA under spinal anesthesia with ITM.

METHODS:

We performed a prospective, double-blinded randomized controlled trial comparing immediate postoperative outcomes after TKA. All patients received combined spinal-epidural (CSE) anesthesia with ITM and multimodal analgesia. The study group received a standardized PAI with 0.5% ropivacaine, clonidine, ketorolac, and epinephrine, while the control group received PAI with saline. Exclusion criteria were revision surgery, inability to receive epidural anesthesia or PAI, patients taking greater than 80 morphine milligram equivalents (MME) daily prior to surgery, and lack of patient consent to participate in the study.

RESULTS:

Sixty-four patients enrolled and completed the study from 2015 to 2021. Thirty-four were randomized to the study group and 30 to the control. There was no difference in mean total postoperative opioid consumption between PAI (125.49 MME) and control (138.80 MME); (p = 0.556). There was also no difference in opioid requirements at 0-24 and 24-48 h between PAI (58.87 and 70.57 MME), and control (70.57 and 69.72 MME); (p = 0.308 and p = 0.556).

CONCLUSION:

This study, while underpowered, demonstrates that PAI does not significantly decrease opioid consumption after TKA compared to placebo injection when utilizing ITM spinal anesthesia. When ITM is used, PAI may be reasonably be excluded from the protocol without affecting opioid requirements.

2025-06-01·NEUROPSYCHOPHARMACOLOGY

Alpha-2 agonism in the locus coeruleus impairs learning driven by negative prediction error

Article

作者: Corbit, Laura H ; Brink, Ashleigh K ; Lui, Simon K C

Abstract:

Refining previous learning when environmental contingencies change is a critical adaptive function. Studies have shown that systemic noradrenaline (NA) manipulations, as well as optogenetic manipulations of the locus coeruleus (LC), the primary source of forebrain NA, can improve long-term retention of appetitive extinction. To determine whether the contribution of NA is specific to extinction or extends to other forms of learning where reward is less than expected, we suppressed LC activity with clonidine, an α2A-adrenergic receptor agonist, in two tasks: compound extinction, where two previously rewarded cues are presented together and no longer rewarded, and overexpectation, where animals are presented with two previously rewarded cues but receive a single reward rather than the expected two. In compound extinction, we found no differences between groups in training, extinction, or a spontaneous recovery test. However, animals that received clonidine reacquired responding to the previously extinguished cue significantly faster than saline-treated animals, suggesting weakened extinction learning. In overexpectation testing, the saline group responded significantly less to a stimulus that had undergone overexpectation relative to a control stimulus, indicating that they had recalibrated their estimation of reward magnitude following training where reward was less than expected. In contrast, clonidine-treated animals did not differ in responding to the overexpectation versus control stimuli, suggesting that clonidine impaired learning resulting from overexpectation. These results demonstrate that activity of the LC is important for learning to reduce responding in both extinction and overexpectation paradigms.

66

项与盐酸可乐定相关的新闻（医药）

2025-05-20

·Business Wire

Fresenius Kabi Introduces Epinephrine Injection, USP, in 30 mg per 30 mL Multi-Dose Vials

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi, an operating company of Fresenius, announced today that Epinephrine Injection, USP, is now available in the United States in 30 mg per 30 mL multi-dose vials. "Fresenius Kabi, an operating company of Fresenius, announced today that Epinephrine Injection, USP, is now available in the United States in 30 mg per 30 mL multi-dose vials...the product launch adds to the company’s offerings of Epinephrine Injection." Epinephrine Injection 30 mg per 30 mL is a prescription medicine used for emergency treatment of allergic reactions (Type 1), including anaphylaxis, in adults and pediatric patients and to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock. The product launch adds to the company’s offerings of Epinephrine Injection. In December 2024, Fresenius Kabi introduced the first generic version of Epinephrine, USP, in a 1 mg per mL vial for U.S. customers. “We are pleased to offer our customers a cost-effective solution that supports quality patient care,” said Arun Verma, president, Fresenius Kabi Region U.S. and Member of the Executive Leadership Team, Fresenius Kabi AG. “At Fresenius Kabi, we are continually striving for new solutions as a trusted partner with the healthcare community.” Epinephrine Injection is manufactured in the U.S., reflecting the company’s commitment to domestic production. Since 2017, Fresenius Kabi has invested nearly $1 billion to expand and modernize advanced U.S. pharmaceutical production and distribution facilities. More than 70% of the units shipped by Fresenius Kabi in the U.S. are drugs listed on the FDA’s Essential Medicines List. To learn more, visit our More in America page. IMPORTANT SAFETY INFORMATION WARNINGS AND PRECAUTIONS Do not inject into buttocks, digits, hands, or feet. Avoid extravasation into tissues, which can cause local necrosis. Monitor patient for acute severe hypertension. Potential for pulmonary edema, which may be fatal. May constrict renal blood vessels and decrease urine formation. May induce potentially serious cardiac arrhythmias or aggravate angina pectoris, particularly in patients with underlying heart disease. Presence of sulfite in this product should not deter use. ADVERSE REACTIONS Most common adverse reactions to systemically administered epinephrine are headache; anxiety; apprehensiveness; restlessness; tremor; weakness; dizziness; sweating; palpitations; pallor; peripheral coldness; nausea/vomiting; and/or respiratory difficulties. Arrhythmias, including fatal ventricular fibrillation, rapid rises in blood pressure producing cerebral hemorrhage, and angina have occurred. To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC at 1-800-551-7176, option 5, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. DRUG INTERACTIONS Drugs that counter the pressor effects of epinephrine include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, ergot alkaloids, and phenothiazine antipsychotics. Drugs that potentiate the effects of epinephrine include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin. Drugs that increase the arrhythmogenic potential of epinephrine include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides. Observe for development of cardiac arrhythmias. Potassium-depleting drugs, including corticosteroids, diuretics, and theophylline, potentiate the hypokalemic effects of epinephrine. USE IN SPECIFIC POPULATIONS Pregnancy: May cause fetal harm. Elderly patients and pregnant women may be at greater risk of developing adverse reactions when epinephrine is administered parenterally. INDICATIONS AND USAGE Epinephrine is a non-selective alpha- and beta-adrenergic agonist indicated: For emergency treatment of allergic reactions (Type 1), including anaphylaxis, in adults and pediatric patients. To increase mean arterial blood pressure in adult patients with hypotension associated with septic shock. This Important Safety Information does not include all the information needed to use Epinephrine Injection, USP safely and effectively. Please see full prescribing information for Epinephrine Injection, USP. About Fresenius Kabi As a global healthcare company, Fresenius Kabi is Committed to Life. The company’s products, technologies, and services are used for the therapy and care of patients with critical and chronic conditions. With more than 41,000 employees and present in more than 100 countries, Fresenius Kabi’s expansive product portfolio focuses on providing access to high-quality and lifesaving medicines and technologies. In Biopharma, Fresenius Kabi offers biosimilars for autoimmune diseases and oncology. With leading market positions in Clinical Nutrition, a broad global portfolio of enteral and parenteral products makes a distinct difference in patients’ nutritional status – notably as the only corporation offering both product groups. In MedTech, the company provides infusion pumps, cell and gene therapy devices, disposables, and more. Fresenius Kabi is a global leader in supplying blood collection bags and devices, supporting blood banks and healthcare facilities worldwide. The company’s I.V. Generics and Fluids for infusion therapy help save millions of lives every year, in emergency medicine, surgery, oncology, and intensive care. Fresenius Kabi takes a holistic approach to healthcare and uniquely combines experience, expertise, innovation, and dedication – making a difference in the lives of 450 million patients annually. In line with the #FutureFresenius strategy, the company is developing, producing, and selling new products and technologies and aspires to expand its position as a leading global provider of therapies, improve patient care, generate sustainable value for stakeholders – shaping the future of healthcare. Fresenius Kabi is an operating company of the Fresenius Group, founded in 1912, along with Helios and Quirónsalud. As ONE team, the companies in the Fresenius Group are committed to providing lifesaving and life-changing healthcare solutions on a global scale. For more information, please visit www.fresenius-kabi.com. To learn about U.S. career opportunities at Fresenius Kabi, visit us at www.fresenius-kabi.com/us/join-us and follow us on LinkedIn and Facebook.

上市批准

2025-05-20

·EINPresswire

Medicine Repurposing Enables Value-Based Insomnia And Pain Therapy; Olumuyiwa Bamgbade, Salem Pain Clinic, Canada

A Promising Case of Medicine Repurposing: Clonidine for Insomnia in Chronic Pain Patients. Olumuyiwa Bamgbade, Salem Pain Clinic, BC, Canada. Clonidine’s ability to deliver multi-dimensional pain and insomnia relief makes it a value-based therapy in integrated care strategies” — Dr. Olumuyiwa Bamgbade SURREY, BC, CANADA, May 20, 2025 / EINPresswire.com / -- In this era where value-based healthcare is shaping the future of medicine, drug repurposing offers a strategic pathway to improve outcomes while minimizing costs. A study published in the Journal of Clinical Sleep Medicine highlights the example that Clonidine, a traditional cardiovascular medication, demonstrates superior results over Zopiclone in treating insomnia in chronic pain patients. The clinical study was conducted by Dr. Olumuyiwa Bamgbade and the Salem Anaesthesia Pain Clinic . It showed that Clonidine, a medicine long used to manage hypertension, is a safe and effective alternative to sedative-hypnotic medication. Unlike Zopiclone, a sedative commonly associated with side effects like amnesia, hallucinations, and poor coordination, Clonidine showed a more favorable safety profile. Clonidine improved sleep initiation, duration, and quality more effectively than Zopiclone. Clonidine was associated with fewer central nervous system side effects. Additionally, patients reported significantly lower pain levels with Clonidine use. These findings have important implications for value-based care. Value-based care emphasizes improving patient outcomes while optimizing resource use. Thus, the study exemplifies how repurposing established medications can unlock new therapeutic benefits without the financial and regulatory burden of developing new drugs. Clonidine’s dual benefit, improving sleep and pain management, aligns with the core tenets of value-based care. Indeed, Clonidine’s ability to deliver multi-dimensional relief has positioned it as a high-value option in integrated care strategies. Dr. Bamgbade is a healthcare leader with an interest in value-based healthcare delivery. He is a specialist physician trained in Nigeria, Britain, the USA, and South Korea. He is an adjunct professor at institutions in Africa, Europe, and North America. He has collaborated with researchers in Nigeria, Australia, Iran, Mozambique, Rwanda, the USA, Kenya, Armenia, South Africa, Britain, Tanzania, Namibia, Zambia, Botswana, China, Ethiopia, Jamaica, and Canada. He has published 45 scientific papers in PubMed-indexed journals. He is the director of Salem Pain Clinic, a specialist and research clinic in Surrey, BC, Canada. Dr Bamgbade and Salem Pain Clinic focus on researching and managing pain, health equity, injury rehabilitation, neuropathy, insomnia, societal safety, substance misuse, medical sociology, public health, medicolegal science, and perioperative care. References Bamgbade OA, Tai-Osagbemi J, Bamgbade DO, Murphy-Akpieyi O, Fadire A, Soni NK, Mumporeze L. Clonidine is better than zopiclone for insomnia treatment in chronic pain patients. J Clin Sleep Med. 2022;18(6):1565-1571. PMID: 35112665. EIN Presswire. Healthcare Leadership Failures Require Metrics and Meritocracy Reforms. Fox 21 News 2025 (April 21). EIN Presswire. The Need to Teach Resourcefulness Initiatives in Human Care Systems. WJHL News 2025 (January 14). Jonker AH, Fetro C, Gogou MC, De Kort M, Stone H, Valentine N, Pasmooij AM. Drug repurposing for rare: Progress and opportunities for the rare disease community. Frontiers in Medicine. 2024;11,1352803. Krishnamurthy N, Grimshaw AA, Axson SA, Choe SH, Miller JE. Drug repurposing: a systematic review on root causes, barriers and facilitators. BMC Health Serv Res. 2022;22(1):970. Wang Y, Aldahdooh J, Hu Y, Yang H, Tang J, Tanoli Z. DrugRepo: A novel approach to repurposing drugs based on chemical and genomic features. Scientific Reports. 2022;12(1):1-13. Olumuyiwa Bamgbade Salem Anaesthesia Pain Clinic +1 778-628-6600 salem.painclinic@gmail.com Visit us on social media: LinkedIn Other Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

临床结果

2025-05-17

·思齐俱乐部

317个药品，集采结果落地

95个中成药未中选产品降价、撤网5月14日，山东省医保局发布《关于执行全国中成药采购联盟集中采购中选结果的通知》，明确5月28日起全省落地中选结果，中选企业5月23日前完成挂网、配送关系建立（中选品种供应清单见文末附1）。第三批全国中成药联盟集采由湖北牵头，31省参与，覆盖20个产品组，涉及丹参片、脂必妥胶囊、益气复脉颗粒等95个通用名产品，共174个药品中选。在喜炎平、穿心莲、穿琥宁、炎琥宁采购组中，炎琥宁注射剂型受药监部门修订说明书内容的影响，协议采购量完成情况可按炎琥宁注射剂型中选药品使用比例进行考核。儿科医院等专科医院炎琥宁注射剂型不纳入执行情况考核范围。四川、新疆、河南省医保局近日也发布了通知，将分别于5月30日、5月30日、5月31日起实施对应中选结果。四川明确在三方购销合同签订15个工作日内，要按不低于合同采购金额的50%进行首次预付，并按规定预付剩余货款。河南要求本次集采同药品名称下已在河南挂网但未在供应清单的药品按照未中选产品挂网管理，其中，价高的，按中选企业报价代表品最终降幅予以等比例降价；价低的，保持原挂网价格不变，规定时间内未调价的予以撤网处理。45种中药饮片新添两省月底落地5月13日，西藏自治区医保局发布《关于开展全国中药饮片联盟集中带量采购中选品种挂网采购工作的通知》，组织在5月13日至5月19日期间开展中选产品配送关系确认及购销协议签订等工作，并于5月20日起全区统一挂网执行。5月9日，广东省医保局发布通知，5月30日起执行全国中药饮片采购联盟集采相关中选结果，采购期原则上为1年，视情况可延长不超过1年。广东要求落实药品集中带量采购医保基金预付等有关要求，医保基金按不低于年度约定采购金额的30%预付给医疗机构；医疗机构要按采购合同与企业及时结清药款，结清时间不得超过交货验收合格后次月底，并履行承诺及承担相应违约责任。各采购平台还要做好中药饮片采购全流程监测工作，跟踪医疗机构的订单和配送情况，不按期配送的及时协调中选企业供应，强化采购和供应监测等。此次联盟集采由山东牵头展开，31省参与，丹参、黄芪、连翘、当归、金银花等45种中药饮片中选，其中，地黄和川芎中选产品数最多，达354个；中选产品数最少的陈皮，也有134个产品中选。联盟中包括山东在内的多个省，如河南、吉林、江西、贵州等，均已在4月下旬陆续开始执行中选结果。40个药品中选结果下月执行5月12日，广西自治区医保局发布《关于做好“六病共管”药品耗材集中带量采购和使用落地工作的通知》，明确6月16日起执行注射用雷替曲塞、尼洛替尼胶囊等17个品种、40个产品的中选结果（中选企业、价格等见文末附2）。5月25日前，中选企业需完成申报挂网；5月26日至6月15日期间，医疗机构将完成与中选企业和配送企业的购销合同签订；医疗机构对该批次预付周转金申请需在7月20日前提交，未申请视为放弃。采购的两年协议期内，医院应优先使用带量采购中选产品，不得以费用控制、使用产品规格数量限制及配送企业开户等为由影响中选产品的采购和使用，不得在进院、库存等环节向企业收取附加费用。高价非中选产品的医保支付标准也面临下调。按照规则，非中选产品中销售价格高于同类中选产品最高中选价格2倍以上的，以同类中选产品最高中选价格的110%作为医保支付标准，且要在两年内渐进调整医保支付标准至不超过同类中选产品的最高中选价格。66个化药，报价在即5月13日，四川省药械招标采购服务中心发布《关于环磷腺苷葡胺等66个化学药品省际联盟带量联动价格申报及公布相关事宜的通知》，相关品种报价将于5月15日（本周四）14:15 ，通过四川药招微信视频号通过直播方式公布。该联盟由四川与重庆、贵州、云南、西藏、青海共六省组成，采购涉及66个化药（名单见文末附3），其中环磷腺苷、曲克芦丁、七叶皂苷等49个为注射剂，复方利血平、尼莫地平等15个为口服常释剂型，以及可乐定贴剂、高锰酸钾外用片剂两个外用制剂。按照规则，联盟将按过评情况对纳入带量联动目录的药品按目录序号区分A、B竞价组，所有获得入围资格的产品，申报价格≤同竞价组获得入围资格有外省中选价格的所有企业外省最低中选价×1.8倍，获得拟中选资格。十七省联盟集采中选结果确定5月13日，河南发布《十七省（区、兵团）药品联盟接续带量采购公告（六）》。该联盟由河南牵头，江西、山西、内蒙古、黑龙江、湖北、湖南、广西、海南、重庆、贵州、云南、陕西、青海、宁夏、新疆（兵团）共17省参与。最终名单共267家企业的586个产品中选（清单见文末下载），覆盖复方利血平、二甲双胍格列吡嗪等71个品种。去年12月，河南公布了十七省联盟集采和首批集采接续集采结果，2月底又对中选结果的申投诉进行了处理。此次公布的最终中选企业供应清单明确，尼莫地平注射剂、己酮可可碱注射剂按照第十批国家组织药品集中采购中选结果执行，本次集采中选结果不再执行。附1：附2：附3：来源：赛柏蓝作者：陈芋责编：遥望点击阅读原文了解更多

带量采购

100 项与盐酸可乐定相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00604	盐酸可乐定	C02AC01 N02CX02 S01EA04	DB00575

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
注意缺陷障碍伴多动	美国	Concordia Pharmaceuticals, Inc.	2009-09-29
偏头痛	英国	-	2006-05-10
血管性头痛	英国	-	2006-05-10
癌症疼痛	美国	Mylan Institutional LLC	1996-10-02
高眼压症	中国	湖北远大天天明制药有限公司	1991-01-01
原发性高血压	日本	Medical Parkland Co., Ltd.	1969-05-15
高血压	日本	Mitsubishi Tanabe Pharma Corp.	1969-05-15
肾性高血压	日本	Medical Parkland Co., Ltd.	1969-05-15

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
化疗性口腔黏膜炎	临床3期	美国	Monopar Therapeutics, Inc.	2021-02-11
化疗性口腔黏膜炎	临床3期	法国	Monopar Therapeutics, Inc.	2021-02-11
化疗性口腔黏膜炎	临床3期	德国	Monopar Therapeutics, Inc.	2021-02-11
化疗性口腔黏膜炎	临床3期	波多黎各	Monopar Therapeutics, Inc.	2021-02-11
化疗性口腔黏膜炎	临床3期	西班牙	Monopar Therapeutics, Inc.	2021-02-11
口咽肿瘤	临床3期	美国	Monopar Therapeutics, Inc.	2021-02-11
口咽肿瘤	临床3期	法国	Monopar Therapeutics, Inc.	2021-02-11
口咽肿瘤	临床3期	德国	Monopar Therapeutics, Inc.	2021-02-11
口咽肿瘤	临床3期	波多黎各	Monopar Therapeutics, Inc.	2021-02-11
口咽肿瘤	临床3期	西班牙	Monopar Therapeutics, Inc.	2021-02-11

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05487196 (CTgov)	临床2期	镇痛	88	Clonidine+Ropivacaine (Clonidine)	餘鹽襯鑰糧鏇衊糧壓觸(願顧獵鏇獵衊鹹積餘繭) = 衊膚襯鏇製構憲艱觸製願鹹齋憲網獵網構鏇構 (觸鑰齋餘憲遞網齋壓襯, 獵淵製構鏇壓鬱壓餘膚 ~ 膚選齋窪齋淵網鹹範構) 更多	-	2025-04-27
				Dexmedetomidine+Ropivacaine (Dexmedetomidine)	餘鹽襯鑰糧鏇衊糧壓觸(願顧獵鏇獵衊鹹積餘繭) = 鏇鏇鹽襯鹹獵鏇獵鬱構願鹹齋憲網獵網構鏇構 (觸鑰齋餘憲遞網齋壓襯, 壓範獵窪觸鹽網夢構遞 ~ 鹹廠糧齋製襯壓淵廠鑰) 更多
NCT05575219 (CTgov)	临床4期	物质戒断综合征	128	Clonidine (Usual Care (Without Protocolized Clonidine Initiation))	齋積範築餘鏇顧範獵構 = 繭顧餘繭範遞鑰鑰獵鹽積憲鑰鑰艱簾餘願齋繭 (糧衊艱鬱願鏇夢鏇構膚, 艱構顧製觸遞蓋築衊製 ~ 衊觸淵廠鏇積襯鹽製膚) 更多	-	2025-01-28
				Clonidine (Intervention (Protocolized Clonidine Initiation))	齋積範築餘鏇顧範獵構 = 構獵繭衊鹽鹹蓋壓夢獵積憲鑰鑰艱簾餘願齋繭 (糧衊艱鬱願鏇夢鏇構膚, 築鑰遞獵餘鬱構膚構艱 ~ 積範蓋鑰選襯觸鑰淵壓) 更多
NCT03109795 (ATLAS, CTgov)	临床4期	焦虑症 \| 高血压	35	Clonidine Pill (Clonidine)	繭蓋積網觸繭觸憲醖艱(憲製壓餘憲製壓獵積簾) = 選網壓構醖廠淵獵顧觸觸積網觸鬱鹽鬱構膚憲 (廠襯淵簾遞鏇築範網齋, 顧遞糧鑰選範築鹽選糧 ~ 鬱遞淵繭餘餘淵構壓夢) 更多	-	2024-07-29
				Hydrochlorothiazide (Hydrochlorothiazide)	繭蓋積網觸繭觸憲醖艱(憲製壓餘憲製壓獵積簾) = 構願鬱簾積廠選膚壓築觸積網觸鬱鹽鬱構膚憲 (廠襯淵簾遞鏇築範網齋, 膚獵製選膚淵獵積選膚 ~ 鹽獵窪鏇齋鹽襯齋遞餘) 更多
ENDO2024	N/A	-	98	Clonidine	製簾淵艱壓網鬱範艱製(鬱鏇選窪觸衊顧網鹽憲) = 38.8% experienced hypotension, with an association found between hypotension and higher GH peaks 製艱鑰獵選獵網膚壓積 (簾衊網積鏇淵鬱淵觸遞 ) 更多	-	2024-06-01
ENDO2024	N/A	copeptin	42	Clonidine	餘簾蓋範窪夢觸蓋鑰選(構壓製餘淵觸夢繭蓋蓋) = 觸蓋選範糧鑰顧襯網簾窪醖壓獵襯鑰窪衊夢蓋 (觸選膚積窪獵蓋築膚鏇 ) 更多	不佳	2024-06-01
				No Clonidine	餘簾蓋範窪夢觸蓋鑰選(構壓製餘淵觸夢繭蓋蓋) = 觸憲齋襯遞襯顧衊醖淵窪醖壓獵襯鑰窪衊夢蓋 (觸選膚積窪獵蓋築膚鏇 ) 更多
FDA_CDER 人工标引	N/A	注意缺陷障碍伴多动	236	Clonidine hydrochloride extended-release 0.2 mg/day (Study 1)	襯遞鏇壓醖壓淵淵觸築(網淵鏇獵襯廠淵選選遞) = 糧選艱鬱鏇蓋糧蓋膚鏇選糧蓋醖窪鏇顧壓築願 (遞壓製鬱觸艱選製鹹膚, 1.38) 更多	积极	2024-05-24
				Clonidine hydrochloride extended-release 0.4 mg/day (Study 1)	襯遞鏇壓醖壓淵淵觸築(網淵鏇獵襯廠淵選選遞) = 衊顧獵膚鑰積艱鹽艱廠選糧蓋醖窪鏇顧壓築願 (遞壓製鬱觸艱選製鹹膚, 1.33) 更多
FDA_CDER 人工标引	N/A	注意缺陷障碍伴多动	135	Clonidine Hydrochloride Extended-Release Tablets (Study 3)	糧範齋製鑰憲廠製齋齋(顧構願鬱蓋衊積艱鹹觸) = 鑰鏇餘選淵鹽艱簾鑰鏇膚獵製選築餘餘鬱範襯 (簾糧齋齋鏇簾選網構膚 )	积极	2024-05-24
				Placebo (Study 3)	糧範齋製鑰憲廠製齋齋(顧構願鬱蓋衊積艱鹹觸) = 衊鏇壓淵積淵構觸蓋鹹膚獵製選築餘餘鬱範襯 (簾糧齋齋鏇簾選網構膚 )
FDA_CDER 人工标引	N/A	注意缺陷障碍伴多动	198	Clonidine hydrochloride extended-release tablets (0.4 mg/day) + Psychostimulant (Study 2)	窪積築糧廠醖築網夢廠(觸範廠鏇鑰繭選襯獵廠) = 範遞積簾範壓築膚願繭遞遞鬱醖艱夢簾襯遞簾 (艱鹹鬱簾糧觸壓膚鹹範, 1.18) 更多	积极	2024-05-24
				Psychostimulant alone (Study 2)	窪積築糧廠醖築網夢廠(觸範廠鏇鑰繭選襯獵廠) = 襯廠鏇齋顧糧憲衊窪憲遞遞鬱醖艱夢簾襯遞簾 (艱鹹鬱簾糧觸壓膚鹹範, 1.24)
NCT01179009 (CTgov)	N/A	难治性抑郁症	20	Clonidine+Ketamine (Ketamine 100-hour Infusion)	選艱選膚鑰簾簾廠膚膚(選遞製選構衊選顧鏇夢) = 選繭範襯壓鹹窪範憲積夢憲襯網選蓋衊壓鬱襯 (醖齋獵獵範願夢構艱醖, 9.5) 更多	-	2023-09-15
				placebo+Clonidine+Ketamine (Ketamine 40-minute Infusion)	選艱選膚鑰簾簾廠膚膚(選遞製選構衊選顧鏇夢) = 觸顧襯選鏇網糧築壓淵夢憲襯網選蓋衊壓鬱襯 (醖齋獵獵範願夢構艱醖, 8.7) 更多
NCT02628626 (CTgov)	临床3期	大便失禁 \| 胆汁酸吸收不良（BAM）	88	Placebo (Placebo)	鑰膚製艱壓衊夢襯鑰觸 = 膚鹹糧鑰積繭築簾憲蓋範醖選簾蓋蓋鑰鹹蓋壓 (窪壓願築選製夢夢淵夢, 鬱蓋簾鹹構範憲鬱顧窪 ~ 簾觸襯淵積構範選艱廠) 更多	-	2023-06-22
				Clonidine+Colesevelam (Colesevelam and Clonidine)	鑰膚製艱壓衊夢襯鑰觸 = 築廠選蓋範鹽鏇觸廠構範醖選簾蓋蓋鑰鹹蓋壓 (窪壓願築選製夢夢淵夢, 鬱餘餘襯醖鹽獵鹹鹽膚 ~ 醖夢鹽積夢積廠壓餘繭) 更多